[ad_1]
Eindhoven, The Netherlands, April 11, 2024 (Globe Newswire) — ONWARD Medical NV (Euronext: ONWD) is developing an innovative A medical technology company that develops spinal cord stimulation therapy. ) today announced that it will host a webcast to present its full-year 2023 financial results and discuss business highlights.
The webcast will be held on April 25, 2024 at 2:00 PM CET / 8:00 AM ET. Moderated by CEO Dave Marver and Interim CFO Khaled Bahi, they will discuss 2023 highlights and provide business updates.
To join the webcast via Zoom, please register using this link.
Participants can also participate by phone.
+32 2 290 9360 (Belgium)
+49 69 3807 9884 (Germany)
+31 20 794 0854 (Netherlands)
+41 22 591 0156 (Switzerland)
+44 203 481 5240 (UK)
+1 346 248 7799 (USA)
Additional phone numbers available
Conference ID: 869 3710 5839
A recording of the webcast will be published on our website following the live event.
To learn more about ONWARD Medical’s commitment to partnering with the SCI community to develop innovative solutions to restore movement, function and independence after spinal cord injury, please visit ONWD.com.
*All ONWARD medical devices and therapies (including but not limited to ARC-IM)®Arc EX®ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are in the research stage and not available for commercial use.
About Onward Medical
ONWARD Medical is a medical technology company that develops treatments to restore movement, function, and independence to people with spinal cord injuries (SCI) and movement disorders. The company received his 10 breakthrough award from the U.S. Food and Drug Administration for the ARC Therapy™ platform, based on his more than 10 years of scientific and preclinical research conducted at leading neuroscience laboratories. The device has been specified.
forward® ARC Therapy, available via external ARC-EX® or embedded ARC-IM® The system is designed to provide targeted and programmed spinal cord stimulation. Positive results were announced in 2023 from the company’s pivotal study, called Up-LIFT, evaluating the ability of transdermal ARC therapy to improve upper extremity strength and function. The Company has submitted a De Novo regulatory application to the FDA for approval of ARC-EX in the United States and is preparing a regulatory application in Europe. In parallel, the company is conducting research using its implantable ARC-IM platform, which demonstrated positive interim clinical outcomes for improved blood pressure control after SCI. Other ongoing research includes the combination of ARC-IM and brain-computer interfaces (BCI) to address multiple symptoms of SCI.
Headquartered in Eindhoven, Netherlands, ONWARD Medical has a science and engineering center in Lausanne, Switzerland, and a U.S. office in Boston, Massachusetts. The company also has an academic partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and the Lausanne University Hospital (CHUV).
ONWARD Medical is listed on Euronext Brussels and Amsterdam (ticker: ONWD).
For more information, visit ONWD.com and connect with us on LinkedIn and YouTube.
Media inquiries:
Aditi Roy, Vice President of Communications
media@onwd.com
Investor inquiries:
Khaled Bahi, Interim CFO
investor@onwd.com
Disclaimer
Certain statements, beliefs and opinions in this press release are forward-looking and reflect the current expectations and projections of future events of the Company or, as appropriate, of the Company’s directors. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. There is a possibility. These risks, uncertainties and assumptions may adversely affect the results and financial impact of the plans and events described herein. Numerous factors, including changes in demand, competition and technology, could cause actual events, performance and results to differ materially from anticipated developments. Any forward-looking statements contained in this press release regarding past trends or activities should not be construed as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release whether as a result of changes in expectations or as a result of changes in events, conditions, assumptions or circumstances. To do. These forward-looking statements are based on. Neither the Company nor any of its advisors or representatives, nor any of its subsidiaries or their officers or employees, provides any warranty that the assumptions underlying such forward-looking statements will be error-free; No responsibility is assumed for the future accuracy of the. Actual events of statements contained in this press release or anticipated developments; You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. All ONWARD medical devices and treatments referenced herein (including but not limited to ARC-IM)®Arc EX®ARC-BCI™ and ARC Therapy™ are in the research stage and are not available for commercial use.
[ad_2]
Source link
